Neuphoria Therapeutics Inc. cash flow to debt ratio of 34.10K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Neuphoria Therapeutics Inc.'s free cash flow has increased -626.05% from $-14.68M last year to $77.23M, signaling increasing performance

Neuphoria Therapeutics Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Neuphoria Therapeutics Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.00 today, signaling strengthened financials

Neuphoria Therapeutics Inc. has a net cash position, so leverage is healthy.

Neuphoria Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Neuphoria Therapeutics Inc. has insufficient data to evaluate this check.

Neuphoria Therapeutics Inc.'s short-term assets of $22.85M exceed its short-term liabilities of $6.41M

Neuphoria Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Neuphoria Therapeutics Inc.'s return on equity of -113.35%, is lower than 15.00%, indicating bad performance

Neuphoria Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Neuphoria Therapeutics Inc. has insufficient public price history to evaluate earnings stability.

Neuphoria Therapeutics Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Neuphoria Therapeutics Inc. has a free cash flow yield of 370.20%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Neuphoria Therapeutics Inc.'s yearly earnings has increased -97.61% since last year from $-15.49M to $-369.63K, signaling increasing performance

Neuphoria Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -71.97% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Neuphoria Therapeutics Inc.'s 3-year revenue CAGR of 244.38% is positive, indicating growing revenue over the past 3 years

Neuphoria Therapeutics Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Neuphoria Therapeutics Inc. has insufficient public price history to evaluate ROE consistency.

Neuphoria Therapeutics Inc. has insufficient data to evaluate this check.

Neuphoria Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Neuphoria Therapeutics Inc. is overvalued relative to its fair value price of 3.62 based on EBITDA multiple model

Neuphoria Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Neuphoria Therapeutics Inc. has insufficient data to evaluate this check.

Neuphoria Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Neuphoria Therapeutics Inc. has a price-to-book ratio of 0.71x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Neuphoria Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue